XENE Xenon Pharmaceuticals Inc.

NASDAQ
$38.93

Xenon Pharmaceuticals Inc. (XENE) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Bullish Insiders bought more than they sold over this window — uncommon at any size.
Cluster activity 2 buyers in the last 30 days 2 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
2
2 transactions
Insiders selling
4
5 transactions
Purchases
$1.7M
45,000 shares
Sales
$1.2M
19,580 shares
Net activity
$481.3K
purchases less sales

How much of that selling was preplanned? 47% planned / 53% discretionary

10b5-1 plan sales $559.3K 4 transactions · 9,580 shares
Discretionary sales $640.6K 1 transaction · 10,000 shares

Largest single sale: $640.6K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 30, 2026 , by Kelly Thomas Patrick .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
MORTIMER IAN PRESIDENT & CEO Buy 30,000 $37.38 $1.1M 49,923
Kelly Thomas Patrick Chief Financial Officer Buy 15,000 $37.32 $559.7K 15,000
KENNEY CHRISTOPHER JOHN 2 fills Chief Medical Officer Sell 10b5-1 7,068 $60.25 $425.8K 702 −91% of holding
GANNON STEVEN Director Sell 10,000 $64.06 $640.6K 1,870 −84.2% of holding
PATOU GARY Director Sell 10b5-1 1,322 $53.14 $70.3K 24,896 −5% of holding
Cannon Gillian Director Sell 10b5-1 1,190 $53.14 $63.2K 1,455 −45% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.